1. Home
  2. Analysis
  3. Ibrance
  4. Heparin-lock-flush

Ibrance and Heparin lock flush drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Ibrance (palbociclib) and Heparin lock flush (heparin sodium). Common drug interactions include fatigue among females.

The phase IV clinical study analyzes what interactions people have when they take Ibrance and Heparin lock flush. It is created by eHealthMe based on reports of 14 people who take the same drugs from the FDA, and is updated regularly.

What is Ibrance?

Ibrance has active ingredients of palbociclib. eHealthMe is studying from 104,433 Ibrance users. Check the latest studies of Ibrance.

What is Heparin lock flush?

Heparin lock flush has active ingredients of heparin sodium. eHealthMe is studying from 750 Heparin lock flush users. Check the latest studies of Heparin lock flush.

On Jan, 28, 2026

14 people who take Ibrance and Heparin lock flush together, and have interactions are studied.

Ibrance and Heparin lock flush drug interactions.

What are the common drug interactions of Ibrance and Heparin Lock Flush, by gender? *:

female:

  1. Fatigue (feeling of tiredness)
  2. Lyme disease (a bacterial infection that is spread to humans by infected ticks)
  3. Abscess limb (limb infection)
  4. Anaemia (lack of blood)
  5. Blood creatinine increased
  6. Brain neoplasm malignant (brain cancer tumour)
  7. Breast inflammation
  8. Breast pain
  9. Cardiac disorder
  10. Cardiac failure congestive

male:

n/a

What are the common drug interactions of Ibrance and Heparin Lock Flush, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Neoplasm progression (growth of tumour)

50-59:

  1. Full blood count decreased

60+:

  1. Fatigue (feeling of tiredness)
  2. Lyme disease (a bacterial infection that is spread to humans by infected ticks)
  3. Anaemia (lack of blood)
  4. Blood creatinine increased
  5. Brain neoplasm malignant (brain cancer tumour)
  6. Breast inflammation
  7. Breast pain
  8. Cardiac disorder
  9. Cardiac failure congestive
  10. Cardiomyopathy (weakening of the heart muscle)

What are the existing conditions these people have? *

  1. Breast Cancer Female: 7 people, 50.00%
  2. Breast Cancer Stage Iv: 3 people, 21.43%
  3. Breast Cancer: 2 people, 14.29%
  4. Pain: 1 person, 7.14%
  5. Nausea (feeling of having an urge to vomit): 1 person, 7.14%
  6. Metastases To Bone (cancer spreads to bone): 1 person, 7.14%
  7. Constipation: 1 person, 7.14%
  8. Chest Pain: 1 person, 7.14%
  9. Breast Cancer Metastatic: 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Ibrance and Heparin lock flush?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Ibrance and Heparin lock flush:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Ibrance:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Heparin lock flush:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Ibrance and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Heparin lock flush and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on palbociclib and heparin sodium (the active ingredients of Ibrance and Heparin lock flush, respectively), and Ibrance and Heparin lock flush (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

Recent personalized studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.